Skip to main content Back to Top


Mupirocin Calcium 2% Nasal Ointment

Products Affected - Description

    • Bactroban 2% nasal ointment, GlaxoSmithKline, 1 gram tube, 10 count, NDC 00029-1526-11

Reason for the Shortage

    • GlaxoSmithKline states the shortage is due to manufacturing issues. GlaxoSmithKline is looking for an alternative supply source.[1]

Available Products

    • There are no presentations available.

Estimated Resupply Dates

    • GlaxoSmithKline has Bactroban Nasal 2% Ointment in 1 gram tubes on long-term back order and the company cannot estimate a release date.[1]

Implications for Patient Care

    • Mupirocin calcium ointment is used intranasally to eradicate nasal colonization of methicillin-resistant Staphylococcus aureus in adult patients and healthcare workers during institutional outbreaks to reduce the risk of infection.[2]


    • Do not share tubes of mupirocin ointment between patients to minimize the risk of cross-contamination.

Alternative Agents & Management

    • During this shortage, consider using mupirocin ointment instead of mupirocin calcium ointment.


    1. GlaxoSmithKline (personal communications). August 5, November 7, 2016; January 27, February 14, May 22, July 28, November 3, 2017; January 10, April 17, July 25, October 23, December 5, 2018; March 12, April 5, July 9, September 24, and November 20, 2019.
    2. GlaxoSmithKline. Bactroban Nasal (mupirocin calcium) ointment 2% [product labeling]. Research Triangle Park, NC: GlaxoSmithKline; 2015


Updated November 20, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created August 13, 2015 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins